ImmunoGen Inc. (IMGN) Drops 9.35% on January 13

Equities Staff |

ImmunoGen Inc. (IMGN) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 9.35% to $9.40, a loss of $-0.97 per share. Starting at an opening price of $10.43 a share, the stock traded between $9.36 and $10.43 over the course of the trading day. Volume was 976,091 shares over 8,534 trades, against an average daily volume of 1.16 million shares and a total float of 86.98 million.

The losses send ImmunoGen Inc. down to a market cap of $817.66 million. In the last year, ImmunoGen Inc. has traded between $19.43 and $5.90, and its 50-day SMA is currently $12.78 and 200-day SMA is $12.56.

Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products.

ImmunoGen Inc. is based out of Waltham, MA and has some 317 employees. Its CEO is Daniel M. Junius.

For a complete fundamental analysis analysis of ImmunoGen Inc., check out’s Stock Valuation Analysis report for IMGN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Kiwa Bio-Tech Products Group Corp

Kiwa Bio-Tech Products Group Corp develops, manufactures, distributes and markets, cost-effective and environmentally safe bio-technological products for agriculture in China.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…